Delpazolid is a next-generation oxazolidinone antibiotic administered through oral and intravenous routes for the treatment of gram-positive bacterial infections including multidrug-resistant tuberculosis infections and pulmonary tuberculosis. Safety and efficacy data are still not mature.

DISEASE BURDEN
In 2021, an estimated 10.6 million people fell ill with TB worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

INTELLECTUAL PROPERTY LANDSCAPE
The primary patent on delpazolid is filed or granted in key countries of manufacture such as India, China and South Africa and is expected to expire in 2029. Secondary patents with an expected expiry date in 2031 are filed or granted in a few LMICs.

SERVICE DELIVERY ENABLERS
Delpazolid is being developed as part of an oral TB treatment with bedaquiline, delamanid, and moxifloxacin, some of which are not widely accessible.

MARKET
This medicine is still in the R&D pipeline and therefore little is known about its potential positioning, pricing, and overall access plans.

MANUFACTURING
There is no adequate data to assess manufacturing complexity.

REGULATORY
The product does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.